Skip to main content
. 2020 May 18;12(5):459. doi: 10.3390/pharmaceutics12050459

Figure 4.

Figure 4

Potency of tested anti-fibrotic compounds to attenuate collagen type I deposition and its de novo biosynthesis in PCKS. (a) Representative photomicrographs of immunohistochemistry for collagen type I in murine and human PCKS before (0 h), after culture (48 h), and after treatment with pirfenidone 2.5 mM, galunisertib 10 µM, or imatinib 10 µM. Scale bars are 50 µm (murine PCKS) or 100 µm (human PCKS). (b) Computerized quantitative analysis of collagen type I protein expression in PCKS, relative to 48 h control slices. Non-parametric Mann–Whitney test was used to compare collagen levels at 0 and 48 h (control slices), # p < 0.05. Kruskal–Wallis test followed by Dunn’s multiple comparisons test was used to compare treated PCKS with 48 h control slices, * p < 0.05. (c) Protein levels of procollagen type I (α1), a marker of newly synthesized collagen, secreted by human healthy and fibrotic PCKS during culture, as measured by ELISA in culture supernatants. (d) Protein levels of procollagen type I (α1) secreted by human PCKS treated with pirfenidone, galunisertib, or imatinib for 48 h. Data are expressed as mean ± SEM, n = 3–4 (murine PCKS) or n = 3–5 (human PCKS); * p < 0.05.